Literature DB >> 16580469

Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology.

Jordan S Orange1, Elham M Hossny, Catherine R Weiler, Mark Ballow, Melvin Berger, Francisco A Bonilla, Rebecca Buckley, Javier Chinen, Yehia El-Gamal, Bruce D Mazer, Robert P Nelson, Dhavalkumar D Patel, Elizabeth Secord, Ricardo U Sorensen, Richard L Wasserman, Charlotte Cunningham-Rundles.   

Abstract

Human immunoglobulin prepared for intravenous administration (IGIV) has a number of important uses in the treatment of disease. Some of these are in diseases for which acceptable treatment alternatives do not exist. In this review we have evaluated the evidence underlying a wide variety of IGIV uses and make specific recommendations on the basis of these data. Given the potential risks and inherent scarcity of IGIV, careful consideration of the indications for and administration of IGIV is warranted.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16580469     DOI: 10.1016/j.jaci.2006.01.015

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  179 in total

1.  Nutritional Status in Agammaglobulinemia: An Italian Multicenter Study.

Authors:  Rosa Maria Dellepiane; Laura Dell'Era; Lorena Vanesa Beilis; Paola Pavesi; Micol Raimondi; Annarosa Soresina; Vassilios Lougaris; Maria Carrabba; Baldassarre Martire; Silvana Martino; Giovanna Russo; Giuseppe Patuzzo; Claudio Pignata; Giuseppe Spadaro; Romina Gallizzi; Marzia Duse; Fernando Giuseppe Specchia; Viviana Moschese; Gian Luigi Marseglia; Maria Cristina Pietrogrande; Giorgio Bedogni; Carlo Agostoni
Journal:  J Clin Immunol       Date:  2015-09-18       Impact factor: 8.317

2.  Clinical profile associated with infections in patients with chronic lymphocytic leukemia. Protective role of immunoglobulin replacement therapy.

Authors:  Andrea Visentin; Nicolò Compagno; Francesco Cinetto; Silvia Imbergamo; Renato Zambello; Francesco Piazza; Gianpietro Semenzato; Livio Trentin; Carlo Agostini
Journal:  Haematologica       Date:  2015-08-20       Impact factor: 9.941

Review 3.  How I treat common variable immune deficiency.

Authors:  Charlotte Cunningham-Rundles
Journal:  Blood       Date:  2010-03-23       Impact factor: 22.113

4.  Decline of antibodies in XLA infant: when to start IVIG.

Authors:  I U Okocha; C G Hanson; J Chinen; W T Shearer
Journal:  Allergy       Date:  2010-09-07       Impact factor: 13.146

5.  Assessment and clinical interpretation of reduced IgG values.

Authors:  Shradha Agarwal; Charlotte Cunningham-Rundles
Journal:  Ann Allergy Asthma Immunol       Date:  2007-09       Impact factor: 6.347

Review 6.  Safety of IGIV therapy and infusion-related adverse events.

Authors:  Mark Ballow
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

7.  Redimune NF Liquid, a ready-to-use, high-concentration intravenous immunoglobulin therapy preparation, is safe and typically well tolerated in the routine clinical management of a broad range of conditions.

Authors:  D Piguet; C Tosi; J-M Lüthi; I Andresen; O Juge
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

Review 8.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

9.  Carimune NF Liquid is a safe and effective immunoglobulin replacement therapy in patients with primary immunodeficiency diseases.

Authors:  Melvin Berger; Charlotte Cunningham-Rundles; Francisco A Bonilla; Isaac Melamed; Johann Bichler; Othmar Zenker; Mark Ballow
Journal:  J Clin Immunol       Date:  2007-05-04       Impact factor: 8.317

10.  Assessment of the efficacy of polyclonal intravenous immunoglobulin G (IVIG) against the infectivity of clinical isolates of methicillin-resistant Staphylococcus aureus (MRSA) in vitro and in vivo.

Authors:  N Farag; L Mahran; K Abou-Aisha; M El-Azizi
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-03-27       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.